P.7.d.001 Cognitive and clinical responses among first episode and chronic schizophrenic patients before and after L'Aquila earthquake

2010 ◽  
Vol 20 ◽  
pp. S627
Author(s):  
R. Pollice ◽  
V. Bianchini ◽  
L. Verni ◽  
M. Mazza ◽  
R. Roncone ◽  
...  
2019 ◽  
Vol 11 (2) ◽  
pp. 55
Author(s):  
Andi Jayalangkara Tanra ◽  
Hawaidah Hawaidah ◽  
Yazzit Mahri ◽  
Saidah Syamsuddin ◽  
Andi Nilawati Usman ◽  
...  

INTRODUCTION: Like the increase of pro-inflammatory cytokines and oxidative stress as schizophrenia pathophysiology, haloperidol also increases RDW and MPV values. Both of these values ​​have been clinicians concern because they are a risk factor for the various type of vascular disease. OBJECTIVE: This study aims to determine the side effect of haloperidol on RDW and MPV values in schizophrenic patients. METHODS: This research method uses observational analytic design with a prospective cohort approach with pre and posts analysis conducted at the Regional Special Hospital of South Sulawesi Province during May - July 2018 in 30 schizophrenic subjects. The subjects were diagnosed as first episode schizophrenia based on ICD 10, blood samples were taken, for RDW and MPV values ​​before and after haloperidol was given at the 4th and 8th weeks. RESULTS: The results showed that the mean RDW value at the 4th week was higher in 15 mg/day haloperidol group (15.8) compared to 7.5 mg/day haloperidol group (15.3) with p<0.05. Mean RDW value taken at 8th week was higher in 15 mg/day haloperidol group (16.4) compared to 7.5 mg/day haloperidol group (15.6) with p<0.001. Mean MPV value taken at 8th week was higher in 15 mg/day haloperidol group (13.3) compared to 7.5 mg/day haloperidol group (11.6) with p<0.001. CONCLUSION: This study showed an increase in the RDW value in schizophrenia subjects prior to the haloperidol administration. RDW ​​and MPV values were higher after haloperidol treatment compares to before haloperidol treatment. The increase of RDW and MPV values tend to be influenced by haloperidol dosage and administration duration.


1991 ◽  
Vol 40 (3) ◽  
pp. 203-207 ◽  
Author(s):  
Sally Szymanski ◽  
Manzar Ashtari ◽  
Joseph Zito ◽  
Gustav Degreef ◽  
Bernhard Bogerts ◽  
...  

1999 ◽  
Vol 9 ◽  
pp. 262-263 ◽  
Author(s):  
M. Poyurovsky ◽  
V. Kris ◽  
G. Weisman ◽  
S. Hromnikov ◽  
V. Isakov ◽  
...  

2021 ◽  
Vol 15 (5) ◽  
pp. 1551-1563
Author(s):  
E. Azizi ◽  
M. Hosseinzadeh ◽  
P. Vahdatian ◽  
A. Adibi ◽  
A. Azizifar ◽  
...  

Background: Schizophrenia is a mental disorder characterized by distortions in thinking, perception, emotions, language, self-sense, and behavior. Recent research suggests that Reactive Oxygen Species (ROS) are involved in the pathophysiology of schizophrenia. Studies have also shown the increased plasma and serum levels of the Trx1 molecule in schizophrenia patients. In the present study, the researchers compared the expression levels of Trx1 mRNA in peripheral blood leukocytes of Iranian schizophrenia patients compared to healthy controls. Methods: First-episode patients (n=35) who met DSM-IV criteria for schizophrenia were recruited from patients referred to psychiatrists in the city of Ilam and Farabi Hospital in Kermanshah. Healthy people were also selected by recruiting people who, according to a psychiatrist, did not have any mental illness. Diagnoses were made for each patient by two independent experienced psychiatrists and confirmed by the Structured Clinical Interview for DSM-IV (SCID). Patients were treated with risperidone for three months and then compared with thirty- five healthy volunteers. Patients were sampled before and after treatment and then by RNA Extraction and DNA synthesis, Trx1 gene expression was performed by real-time PCR method. Results: Comparison of Trx1 gene expression in PBMCs of schizophrenic patients before and after treatment with the control group showed that the expression of Trx1 gene of the “before” treatment group was significantly increased compared with that of the control group (P= 0.0007). Also, Trx1 gene expression in PBMCs of “before” and “after “groups showed that Trx1 gene expression of “after” group was significantly decreased compared to the “before” group (P= 0.014). These results showed that the mean of positive, negative, and general psychopathology was reduced significantly in schizophrenic patients before and after treatment in all three cases (P <0.001). Conclusion: the expression of TRX in PBMCs of schizophrenic patients decreased after risperidone treatment. This reduction of expression was statistically significant and indicates the possible effect of risperidone on the expression of the TRX gene in PBMCs of these patients and decreased gene expression is associated with reduced symptoms. Confirmation of the achievement of this study requires further research. Key words: Schizophrenia, Thioredoxin, Risperidone


1999 ◽  
Vol 38 (1) ◽  
pp. 61-70 ◽  
Author(s):  
Barbara Sperner-Unterweger ◽  
Alexandra Whitworth ◽  
Georg Kemmler ◽  
Wolfgang Hilbe ◽  
Josef Thaler ◽  
...  

1996 ◽  
Vol 246 (5) ◽  
pp. 249-255 ◽  
Author(s):  
M. Albus ◽  
W. Hubmann ◽  
Ch. Ehrenberg ◽  
U. Forcht ◽  
F. Mohr ◽  
...  

2002 ◽  
Vol 252 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Steffen Moritz ◽  
◽  
Burghard Andresen ◽  
Christian Perro ◽  
Marc Schickel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document